CDTX
Price
$20.70
Change
-$2.11 (-9.25%)
Updated
Dec 18, 04:59 PM (EDT)
RNAC
Price
$18.52
Change
+$0.21 (+1.15%)
Updated
Dec 18, 03:22 PM (EDT)
Ad is loading...

CDTX vs RNAC

Header iconCDTX vs RNAC Comparison
Open Charts CDTX vs RNACBanner chart's image
Cidara Therapeutics
Price$20.70
Change-$2.11 (-9.25%)
Volume$4.69K
CapitalizationN/A
Cartesian Therapeutics
Price$18.52
Change+$0.21 (+1.15%)
Volume$100
CapitalizationN/A
CDTX vs RNAC Comparison Chart
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. RNAC commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a Hold and RNAC is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (CDTX: $22.81 vs. RNAC: $18.31)
Brand notoriety: CDTX and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 119% vs. RNAC: 126%
Market capitalization -- CDTX: $249.52M vs. RNAC: $465.35M
CDTX [@Biotechnology] is valued at $249.52M. RNAC’s [@Biotechnology] market capitalization is $465.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.68B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 1 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • CDTX’s FA Score: 1 green, 4 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, CDTX is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 3 TA indicator(s) are bullish while RNAC’s TA Score has 5 bullish TA indicator(s).

  • CDTX’s TA Score: 3 bullish, 4 bearish.
  • RNAC’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, both CDTX and RNAC are a bad buy in the short-term.

Price Growth

CDTX (@Biotechnology) experienced а +2.89% price change this week, while RNAC (@Biotechnology) price change was -19.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.60%. For the same industry, the average monthly price growth was +1.53%, and the average quarterly price growth was +3.09%.

Reported Earning Dates

CDTX is expected to report earnings on Aug 13, 2024.

RNAC is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (-3.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNAC($465M) has a higher market cap than CDTX($250M). CDTX YTD gains are higher at: 43.640 vs. RNAC (-11.469). CDTX has less debt than RNAC: CDTX (4.65M) vs RNAC (10.5M).
CDTXRNACCDTX / RNAC
Capitalization250M465M54%
EBITDAN/AN/A-
Gain YTD43.640-11.469-381%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total Debt4.65M10.5M44%
FUNDAMENTALS RATINGS
CDTX vs RNAC: Fundamental Ratings
CDTX
RNAC
OUTLOOK RATING
1..100
8417
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3553
P/E GROWTH RATING
1..100
10044
SEASONALITY SCORE
1..100
8595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDTX's Valuation (32) in the Biotechnology industry is significantly better than the same rating for RNAC (99). This means that CDTX’s stock grew significantly faster than RNAC’s over the last 12 months.

CDTX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RNAC (100). This means that CDTX’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's SMR Rating (97) in the Biotechnology industry is in the same range as CDTX (100). This means that RNAC’s stock grew similarly to CDTX’s over the last 12 months.

CDTX's Price Growth Rating (35) in the Biotechnology industry is in the same range as RNAC (53). This means that CDTX’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for CDTX (100). This means that RNAC’s stock grew somewhat faster than CDTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXRNAC
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 13 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with PIRS. These tickers have moved in lockstep 96% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then PIRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
-1.93%
PIRS - CDTX
96%
Closely correlated
N/A
WINT - CDTX
94%
Closely correlated
-3.77%
NBY - CDTX
93%
Closely correlated
-4.86%
NCNA - CDTX
93%
Closely correlated
+1.19%
SNPX - CDTX
93%
Closely correlated
-1.99%
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with PIRS. These tickers have moved in lockstep 94% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then PIRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-2.71%
PIRS - RNAC
94%
Closely correlated
N/A
WINT - RNAC
94%
Closely correlated
-3.77%
NCNA - RNAC
92%
Closely correlated
+1.19%
CDTX - RNAC
92%
Closely correlated
-1.93%
NBY - RNAC
91%
Closely correlated
-4.86%
More